Retatrutide: The Triple Agonist Thats Redrawing the Map of Obesity Medicine Updated with TRIUMPH-1 and TRANSCEND-T2D-1 Phase 3 data presented at the ADA 86th Scientific Sessions (June 2026) The Short Version Retatrutide (LY3437943, Eli Lilly) is an investigational, once-weekly subcutaneous peptide that hits three metabolic receptors at once: GIP, GLP-1, and glucagon
Theyll know their injection has started when the yellow bar starts moving
Type 1 diabetes Tresiba (or another basal insulin) is essential for type 1 diabetes management
Dry mouth is not just uncomfortable
In animal cells, this pairing is often imperfect, which has a profound biological result: a single miRNA species can recognize and regulate the expression of hundreds of different mRNA targets [34]
GLP-1 agonists primarily cause gastrointestinal effectsnausea, vomiting, constipation, or diarrheathat typically subside within weeks as the body adjusts